Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes
- 15 May 2005
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 10 (10) , 703-710
- https://doi.org/10.1016/s1359-6446(05)03460-4
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- First-phase insulin secretion: does it exist in real life? Considerations on shape and functionAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetesDiabetes/Metabolism Research and Reviews, 2004
- Standards of Medical Care in DiabetesDiabetes Care, 2004
- Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db MiceThe Journal of Pharmacology and Experimental Therapeutics, 2003
- GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamicsBritish Journal of Pharmacology, 2003
- Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1Diabetes/Metabolism Research and Reviews, 2002
- Postprandial Blood GlucoseDiabetes Care, 2001
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999